PDZRN3

Across TCGA pan-cancer cohorts, PDZRN3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDZRN3 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDZRN3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PDZRN3 expression acts as an unfavorable survival marker.

PDAC, UCEC, and LSCC are the cancer types where PDZRN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.282	0.659	.010	18	view →
UCEC	OS	Median	II,III,IV	0.567	1.000	.004	12	view →
LSCC	DFS	Median	II,III,IV	0.529	0.833	.010	6	view →
GBM	OS	Quartile	All	0.727	0.938	.023	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDZRN3–PDAC (OS)

Open the PDAC breakdown →